Literature DB >> 12495208

New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors.

John S Oxford1, Patricia Novelli, Armine Sefton, Robert Lambkin.   

Abstract

The mushroom shaped outer spike protein of influenza, neuraminidase, was first discovered nearly 60 years ago. Its importance in viral replication was soon recognised both at the point of viral release from the cell and also enabling passage of virus through nasal fluid to reach the cell. The enzyme active site was identified by x-ray crystallography, allowing an atomic study of interaction of enzyme with the sialic acid substrate. Analogues could then be identified and synthesized and became a focused target for antivirals. With the current threat of bioterrorism and the potential for the emergence of a new pandemic strain in the near future, efforts are underway to develop more potent second-generation anti-neuraminidase inhibitors with enhanced protective and therapeutic effects. Here we review older and newer neuraminidase inhibitors and the role that they will play in the fight against influenza in its epidemic and pandemic face.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495208     DOI: 10.1177/095632020201300401

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  4 in total

1.  Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the Netherlands.

Authors:  M Nuño; G Chowell; A B Gumel
Journal:  J R Soc Interface       Date:  2007-06-22       Impact factor: 4.118

2.  Cross-protection of influenza A virus infection by a DNA aptamer targeting the PA endonuclease domain.

Authors:  Shuofeng Yuan; Naru Zhang; Kailash Singh; Huiping Shuai; Hin Chu; Jie Zhou; Billy K C Chow; Bo-Jian Zheng
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 3.  A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.

Authors:  John Oxford; Shobana Balasingam; Rob Lambkin
Journal:  J Antimicrob Chemother       Date:  2003-12-19       Impact factor: 5.790

Review 4.  Na+/K+-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection.

Authors:  Kauê Francisco Corrêa Souza E Souza; Bianca Portugal Tavares Moraes; Izabel Christina Nunes de Palmer Paixão; Patrícia Burth; Adriana Ribeiro Silva; Cassiano Felippe Gonçalves-de-Albuquerque
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.